Introduction
A major effect of insulin is to stimulate glucose transport into muscle and adipose tissue. This stimulation is due largely, if not entirely, to the translocation of one isotype of the glucose transporter, GLUT 4 , from an intracellular vesicular pool to the plasma membrane [ 1, 2] . This article reviews the current state of knowledge about insulin signalling pathways as they relate to the translocation of GLUT 4 and the stimulation of glucose transport.
Insulin receptor
The insulin receptor is a ligand-activated tyrosine kinase ( Figure 1 ). Several studies, using cultured cells expressing mutant forms of the receptor that lack kinase activity, have shown a requirement of the kinase activity for insulin stimulation of transport [3] . However, since the cell types employed do not contain GLUT 4 and show only a modest stimulation of glucose transport in response to insulin (typically less than 2-fold stimulation, compared with 30-fold stimulation in adipocytes), these studies do not directly address the issue of the requirement of the tyrosine kinase activity for GLUT 4 translocation. Better evidence for the requirement of the tyrosine kinase activity is the insulin resistance seen in some individuals with mutant insulin receptors lacking tyrosine kinase activity [4, 5] .
Insulin receptor substrate-I
Insulin receptor substrate-1 (IRS-l), the principal substrate of the insulin receptor, is phosphorylated at multiple tyrosine residues within seconds of insulin binding. Tyrosine phosphorylation creates binding sites for a number of src homology 2 (SH2)-domain-containing signalling proteins, including phosphatidylinositol (PI) 3-kinase (PI3K), the phosphotyrosine phosphatase Syp, and two adaptor proteins, Grb2 and Nck (Figure 1 ). Grb2 is Abbreviations used: CHO, Chinese hamster ovary; EGE', epidermal growth factor; IRS-1, insulin receptor substrate-1; MAPK, mitogen-activated protein kinase; MAPKK, MAPK kinase; PI, phosphatidylinositol; PI3K, P13-kinase; PKC, protein kinase C; PMA, phorbol 13-myristate 12-acetate; SH2, src homology 2; Tyr(P), phosphorylated tyrosine. 'To whom correspondence should be addressed. a subunit of the Ras guanine nucleotide releasing factor Sos; the function of Nck is not known. IRS-1 thus acts as a dockingjeffector protein for a group of SH2-domain-containing proteins (reviewed in
The rapidity of its tyrosine phosphorylation and its ability to trigger several signalling pathways makes IRS-1 an attractive candidate to be a component in the pathway for stimulation of glucose transport. However, to date the evidence supporting an involvement of IRS-1 is only correlative. In one study, depression of IRS-1 levels in 3T3-Ll adipocytes by prolonged treatment with insulin, dexamethasone, actinomycin D, cycloheximide or 1-methyl-3-isobutylxanthine correlated well with a decrease in the rate of insulin-stimulated glucose transport [9] . In the future, a more definitive evaluation of the role of IRS-1 may be possible through microinjection of the phosphotyrosine form of this protein into adipocytes or myocytes followed by examination of GLUT 4 translocation (see below). The availability of purified recombinant IRS-1, which can be phosphorylated with purified recombinant insulin receptor kinase [ 111, makes this approach feasible.
[6-81).
P13K
Insulin rapidly (within 2 min) increases the levels of PI( 3,4)P, and P1(3,4,5)P3 in rat adipocytes, presumably as a result of the activation of PI3K due to its association with IRS-1 (Figure 1) [ 10,111. A role for PI3K in stimulation of glucose transport is suggested by the sequence similarity of its llOkDa catalytic subunit to the yeast Vps34 gene product [12] . This latter protein, which is also a PI3K, is required for sorting of proteins to the yeast vacuole [13] . Thus a role for PI3K in the trafficking of GLUT 4 to the plasma membrane is plausible.
One study that addresses this issue used the PI3K inhibitor wortmannin to inhibit PI3K in rat adipocyte and then monitored the effect on insulinstimulated glucose transport [ 14,151. Treatment of rat adipocytes with 0.1 p M wortmannin abolished insulin-stimulated glucose transport, but was without effect on basal transport rates. This result was attributed to the inhibition of PI3K activity, since wortmannin was an effective inhibitor of adipocyte PI3K in vitro and it did not inhibit the tyrosine phosphorylation of the insulin receptor or IRS-1 in Figure I 
Insulin-signalling pathways potentially relevant to stimulation of glucose transport by insulin
The Tyr(P) form of IRS-I associates with SH2-domain proteins and initiates several signalling pathways. pp90rsk and pp70 S6K refer to the 90 kDa and 70 kDa ribosomal 56 kinases respectively.
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71i7lo [ 151. While this data is suggestive of an involvement of P13K, it was not established that wortmannin inhibited production of PI(3,4)PL or PI(3.4,S)P; in vivo or that GLIJT 4 translocation was inhibited; both of these criteria need to be met if a rigorous conclusion is to be reached. H.p.1.c. analysis of lipid products and the assessment of GI,IJT 4 levels at the plasma membrane can resolve these issues.
A second study of this type examined the effect of wortmannin on insulin-stimulated translocation of an epitope-tagged form of GLUT 4 expression in Chinese hamster ovary (CHO) cells [16] . In this case, insulin-stimulated translocation was measured directly, and 0.1 p M wortmannin inhibited this completely. However, the relevance of this study is made ambiguous by the facts that CHO cells do not normally express GLUT 4 and that the degree of translocation (3.0-fold increase in the plasma membrane) is much less than that in adipocytes (30-fold) .
A more fundamental and general problem in the interpretation of a positive result obtained with an inhibitor, such as wortmannin, in intact cells is that the inhibitor may be acting through another, unknown site. In this regard, the interpretation of a negative result with an inhibitor is more conclusive (see discussion of pp70 S6 kinase below). More selective approaches to inhibit or activate P13K in vzvo are now needed to substantiate its involvement in GLUT 4 translocation.
Ras/Raf
Insulin, like a number of growth factors, elevates the level of the CTP form of Ras, and thereby triggers the activation of a kinase cascade consisting of Raf, the mitogen-activated protein kinase kinase (MAPKK), mitogen-activated protein kinase (MAPK) and the 90kDa ribosomal S6 kinase (pp90rsk) (Figure 1) [8, 17, 18] . The pathway for the elevation of the GTP form of Ras by insulin appears to be stimulation of the guanine nucleotide release factor Sos. This stimulation may occur both as the result of the binding of the phosphorylated tyrosine [Tyr(P)] form of IRS-1 to Grb2 (Figure 1 ) and as a result of the binding to Grb2 of the Tyr(P) form of the protein Shc, which is also generated in response to insulin [8, 19] . Although the pathway from Ras-GTP to pp90rsk is represented as a linear one (Figure l) , any component in it could potentially be a branch point leading to the stimulation of glucose transport.
T o address the role of Ras in insulin signalling of GLUT 4 translocation several approaches have been taken. The effect of stable expression, in 3T3-L1 adipocytes, of an activated mutant N-Ras (Lys-61) on the subcellular distribution of GLUT 4 has been examined [ZO] . In marked contrast to the parental cell line, GLUT 4 was located predominantly in the plasma membrane of cells in the basal state. This finding could indicate a role for Ras in stimulation of glucose transport. However, the situation is complicated by the observation that the GLUT 4 level in the transfected cells was only 5%
of that in the parental cell line. A subsequent study, using the microinjection approach (see below), has provided strong evidence that acutely activated Ras does not trigger GLUT 4 translocation in 3T3-Ll adipocytes. This discrepancy illustrates the point that because there are likely to be many changes upon stable expression of an active signalling protein, a positive effect with this approach cannot be used to decide unambiguously that a particular signalling protein is required for an acute effect like GLUT 4 translocation.
In a different approach, an activated mutant Ras (G12V) and dominant negative inhibitory mutant Ras (S17N) were microinjected into 3T3-Ll adipocytes, and the extent of GLUT 4 translocation subsequently measured by a plasma-membrane sheet assay that detects GLUT 4 in the plasma membrane by immunofluorescence [21] . Both Ras mutants were without effect on basal or insulinstimulated GLUT 4 translocation. The same result was obtained upon microinjection of a neutralizing monoclonal antibody against Ras. Control experiments demonstrated that each microinjected Ras and the monoclonal antibody were functional with regard to effects on the expression and subcellular localization of the GLUT 1 isotype. The results with the dominant negative inhibitory mutant and the neutralizing antibody in particular argue strongly that Ras does not participate in signalling GLUT 4 translocation: it could be postulated that the activated mutant Ras did not trigger translocation because both Ras and a second signalling component are required, but in this case the inhibitory Ras mutant and the neutralizing antibody should still block the process.
In another microinjection study, done with isolated cardiac myocytes, the same activated mutant Ras (G12V) and the same neutralizing antibody were injected, and the transport of 2-deoxyglucose into the injected cells was subsequently assayed by an enzymic amplification method measuring 2-deoxyglucose-&phosphate in single cells [22] . The activated mutant Ras stimulated glucose transport to the same extent as insulin ( -5-fold), and the Ras-neutralizing antibody inhibited insulin-stimulated glucose transport by -65%. Thus, in contrast to results in 3T3-IJ1 adipocytes, these data from microinjection support a role for Ras.
The basis for the different conclusions in the two studies remains to be determined. The method used with cardiac myocytes does not measure GLUT 4 translocation directly, and other effects may contribute to the measured transport activity. In this regard, there is evidence that activated Ras increases both the expression and the plasmamembrane localization of the GLUT 1 transporter isotype [20, 21] and cardiac myocytes contain GLUT 1 as well as GLUT 4 [23] .
The serine/threonine kinase Raf is activated by the elevation of RasSGTP (Figure 1) . The role of Raf in GLUT 4 translocation has been investigated by constitutive expression in 3T3-Ll adipocytes of a mutant active Raf protein kinase (oncogenic 133.5 Raf, the form with an N-terminal truncation) [24] . This expression did not affect either the total GLUT 4 level or the stimulation of GLUT 4 translocation to the plasma membrane in response to insulin. The active Raf was functional since both the total amount of GLUT 1 and the amount at the plasma membrane in the absence of insulin were increased. Thus, while Raf plays a role in regulation of GLUT 1 expression and distribution, it is not sufficient per se to elicit translocation of GLUT 4.
MAPWpp9Orsk
The serine/threonine kinases MAPK and pp90rsk lie at the distal end of the kinase cascade (Figure 1 ). Maximal activation of MAPK (3-%fold) and pp90rsk (3-6-fold) occurs within 5 min of insulin treatment of rat and 3T3-Ll adipocytes, with acti-vation of pp90rsk lagging slightly behind that of MAPK . Both time courses of activation are rapid enough to consider a role for these kinases in insulin stimulation of glucose transport, which reaches its maximal level -10 min after insulin addition. However, there is evidence that the activations of MAPK and pp90rsk are not sufficient for stimulation of glucose transport. Both rat and 3T3-I, 1 adipocytes possess epidermal growth factor (EGF) receptors (5000/cell in rat [28] ; 30 000/cell in 3T3-I, 1 adipocytes [ 291). In 3T3-I, 1 adipocytes, although EGF was found to activate MAPK and pp90rsk to the same extent and over a similar time course as insulin, EGF does not significantly stimulate glucose transport ( < 2-fold) or the translocation of GLUT 4 to the plasma membrane [26, 27] . Similarly, with rat adipocytes, EGF caused no significant stimulation of glucose transport or GLUT 4 translocation, although in this case the activation of the kinases was not examined [28] . These data show a lack of correlation between activation of MAPK/ pp90rsk and GLUT 4 translocation, but they do not entirely eliminate a role, since multiple signals may be needed for translocation to occur.
pp70 S6 kinase
In addition to activating the kinase cascade, insulin also causes the phosphorylation and thereby the activation of a 70kDa ribosomal S6 kinase. The pathway leading to activation of pp70 S6K is not known, but it does not involve MAPK or pp90rsk [30] [31] [32] [33] . In 3TR-I,1 adipocytes, the time course of activation of pp70 S6K approximately parallels the time course for activation of glucose transport 126,331, and thus pp70 S6K could participate in GLUT 4 translocation. 1 lowever, evidence against an involvement of pp70 S6K has come from a study with the macrolide rapamycin, which blocks the activation of pp70 S6K [ 33 1. In rapamycin-treated RT3-1,l adipocytes, insulin activation of pp70 S6K was abolished but insulin-stimulated glucose transport and GI,IJT 4 translocation to the plasma membrane were unaffected. Thus activation of pp70 S6K is not required for insulin-stimulated glucose transport. It remains possible that other, as yet unidentified, components in the pathway for pp70 S6K activation are required for GLIJT 4 translocation, since the site of action of rapamycin in this pathway is not yet known.
Protein kinase C
Consideration of a possible role for a protein kinase C (PKC) in insulin-stimulated GLUT 4 translocation and glucose transport is complicated by the fact that there are at least 12 isoforms of this kinase [34] . These differ in tissue distribution, activators and substrate proteins. Moreover, the issue of whether insulin activates any PKC isoforms remains controversial, with different groups obtaining conflicting results [35] [36] [37] [38] . Phorbol 12-myristate 13-acetate (PMA), a compound which activates some but not all the PKC isotypes, has been used to examine the role of this kinase. PMA causes some translocation of GLUT 4 to the plasma membrane in rat and 3T3-1,l adipocytes. However, the extent of translocation is only -30% of that obtained with insulin, whether assessed by cell-surface labelling of GLUT 4 or by subcellular fractionation, and the stimulation of glucose transport is only -10% of that observed in response to insulin [39-411. Thus, insulin activation of a PMA-responsive PKC isotype does not appear to be sufficient to account for GLUT 4 translocation. It is of interest that the < isotype of PKC can be activated by the lipid products of the PI3K reaction in vitro [42] . This finding suggests that insulin could activate this isoenzyme in vzvo.
Given the current interest in PI3K and its relation to membrane trafficking, a role for the I; isoenzyme in GLUT 4 translocation should be explored.
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Conclusion
Knowledge of pathways of signal transduction from the insulin receptor is rapidly expanding (Figure 1 ).
However, to date, no component of these pathways has been conclusively shown to be required for insulin-stimulated GLUT 4 translocation. There is suggestive evidence that IRS-1 and PI3K participate. It is also possible that there is an undiscovered signalling pathway from the insulin receptor and that this is required for GLUT 4 translocation.
Two general approaches have been used to examine whether a particular protein has a role in GLIJT 4 translocation. One has been to activate the protein selectively and determine whether translocation is triggered. This approach will never be successful if translocation requires the participation of several signalling pathways. The other approach has been to inhibit the protein selectively and determine whether insulin-stimulated translocation is blocked. This approach has the advantage that it allows separate identification of each participating component and also that the lack of an effect on GLUT 4 translocation shows that the inhibited protein is not required.
Microinjection of individual myocytes and adipocytes followed by measurement of glucose transport or GLUT 4 translocation is a new experimental approach in this area that is likely to be especially fruitful [Zl-231. It has the advantage that the effects of individual components can be examined on a relatively rapid time scale, similar to that of GLUT 4 translocation.
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